Anna Sundlöv

Lund University

Sweden

Research Interests

Explore related searches

Professors in Sweden Professors in Medical Imaging Medical Imaging professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (11)

Katarina Sjögreen Gleisner

Full professor

Lund University

SWEDEN

View details

Daniel Roth

Lund University

SWEDEN

View details

Marlene Malmström

Lund University

SWEDEN

View details

Morten Ladekarl

Aalborg University

DENMARK

View details

Peter Bernhardt

Professor

University of Gothenburg

SWEDEN

View details

Kristian Valind

Lund University

SWEDEN

View details

Michael Ljungberg

Professor

Lund University

SWEDEN

View details

Anni Gålne

Lund University

SWEDEN

View details

René Horsleben Petersen

Københavns Universitet

DENMARK

View details

Johan Gustafsson

Lund University

SWEDEN

View details

Seppo W. Langer

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Anna Sundlöv

Research Interests

Explore related searches

Contact this professor

Articles (16)

NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms

Retrospective evaluation of the predictive value of tumour burden at baseline [ 68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE

Optimal follow-up with somatostatin receptor PET/CT imaging in patients with small intestinal neuroendocrine tumours

AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT

Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms

Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms

Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based <sup>177</sup>Lu-DOTATATE treatment of NET patients

Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE

Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres

Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy

The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms

Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours

Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment

Collaborators (11)

Katarina Sjögreen Gleisner

Daniel Roth

Marlene Malmström

Morten Ladekarl

Peter Bernhardt

Kristian Valind

Michael Ljungberg

Anni Gålne

René Horsleben Petersen

Johan Gustafsson

Seppo W. Langer

Make your next move.